An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction

This article has been Reviewed by the following groups

Read the full article

Abstract

SARS-CoV-2 enters host cells through an interaction between the spike glycoprotein and the angiotensin converting enzyme 2 (ACE2) receptor. Directly preventing this interaction presents an attractive possibility for suppressing SARS-CoV-2 replication. Here, we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement. Ty1 binds the RBD with high affinity, occluding ACE2. A cryo-electron microscopy structure of the bound complex at 2.9 Å resolution reveals that Ty1 binds to an epitope on the RBD accessible in both the ‘up’ and ‘down’ conformations, sterically hindering RBD-ACE2 binding. While fusion to an Fc domain renders Ty1 extremely potent, Ty1 neutralizes SARS-CoV-2 spike pseudovirus as a 12.8 kDa nanobody, which can be expressed in high quantities in bacteria, presenting opportunities for manufacturing at scale. Ty1 is therefore an excellent candidate as an intervention against COVID-19.

Article activity feed

  1. SciScore for 10.1101/2020.06.02.130161: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variableIn brief, the adult male alpaca Tyson at PreClinics, Germany, was immunized 4 times in a 60-day immunization schedule.
    Cell Line AuthenticationContamination: All cell lines used for experiments were negative for Mycoplasma as determined by PCR.

    Table 2: Resources

    Antibodies
    SentencesResources
    Bound nanobodies were detected with anti-E tag (Bethyl laboratories) secondary antibody.
    anti-E tag
    suggested: None
    Cells were incubated with anti-dsRNA antibody (1:2000, J2 Scicons) for 1 hour at room temperature followed by 1 hour staining with the secondary antibody anti-mouse-Alexa Fluor 488 (1:2000, Thermo Fisher Scientific), Hoechst (1:1000, Invitrogen) and Ty1-AS635P (0.05 μg/mL).
    anti-dsRNA
    suggested: (Millipore Cat# MABE1134, RRID:AB_2819101)
    anti-mouse-Alexa
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    A HEK293T cell line engineered to overexpress human ACE2 (HEK293T-ACE2) was generated by the lentiviral transduction of HEK293T cells.
    HEK293T
    suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)
    TG1 cells (Lucigen) were transformed with this library by electroporation.
    TG1
    suggested: RRID:CVCL_0P34)
    Approximately 15,000 HEK293T-ACE2 cells were then added to each well and the plates were incubated at 37°C for 48 hours.
    HEK293T-ACE2
    suggested: None
    Immunofluorescence: Vero E6 cells were seeded onto coverslips in a 24-well plate and incubated overnight at 37°C/5% CO2.
    Vero E6
    suggested: None
    Software and Algorithms
    SentencesResources
    Fluorescence was quantified using a BD FACSCelesta and the FlowJo software package.
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)
    Coverslips were mounted in mounting media and images were obtained using Zeiss Axiovert microscope and processed using Adobe Photoshop.
    Adobe Photoshop
    suggested: (Adobe Photoshop, RRID:SCR_014199)
    Extracted particles were imported into cryoSPARC v2.15.036 for 2D classification, 3D classification and non-uniform 3D refinement.
    cryoSPARC
    suggested: (cryoSPARC, RRID:SCR_016501)
    Structure refinement and manual model building were performed using COOT and PHENIX44 in interspersed cycles with secondary structure and geometry restrained.
    COOT
    suggested: (Coot, RRID:SCR_014222)

    Results from OddPub: Thank you for sharing your code and data.


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.